Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1-4

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 15; no. 9; p. 1140
• Main Authors: Yang, Aimin, Lau, Eric S H, Wu, Hongjiang, Ma, Ronald C W, Kong, Alice P S, So, Wing Yee, Luk, Andrea O Y, Fu, Amy W C, Chan, Juliana C N, Chow, Elaine
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.09.2022; MDPI
• Subjects: Acidosis; Analysis; Bias; cardiovascular disease; Chronic kidney failure; Complications and side effects; Diabetes; Dosage and administration; Dose-response relationship (Biochemistry); Drug dosages; Drug therapy; end-stage kidney disease; Forecasts and trends; Glomerular filtration rate; Health aspects; Kidney diseases; lactic acidosis; Metformin; Mortality; Risk factors; Testing; Type 2 diabetes; China; lactic acidosis; mortality; cardiovascular disease; metformin; end-stage kidney disease; diabetes

Type 2 diabetes (T2D)-associated end-stage kidney disease (ESKD) is a global burden, while the renoprotective effects of metformin remain controversial. In a population-based cohort (2002-2018) including 96,643 patients with T2D observed for 0.7 million person-years, we estimated the risk associatio...